Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
BLM$_1$: A Boundless Large Model for Cross-Space, Cross-Task, and Cross-Embodiment Learning
arXiv:2510.24161v1 Announce Type: new Abstract: Multimodal large language models (MLLMs) have advanced vision-language reasoning and are increasingly deployed in embodied agents. However, significant limitations remain: MLLMs generalize poorly across digital-physical spaces and embodiments; vision-language-action models (VLAs) produce low-level actions yet lack robust high-level embodied reasoning; and most embodied large language models (ELLMs) are constrained to digital-space with poor genera
-
cs.AI, q-bio.NC updates on arXiv.org
-
Integrating Genomics into Multimodal EHR Foundation Models
arXiv:2510.23639v1 Announce Type: cross Abstract: This paper introduces an innovative Electronic Health Record (EHR) foundation model that integrates Polygenic Risk Scores (PRS) as a foundational data modality, moving beyond traditional EHR-only approaches to build more holistic health profiles. Leveraging the extensive and diverse data from the All of Us (AoU) Research Program, this multimodal framework aims to learn complex relationships between clinical data and genetic predispositions. The
Integrating Genomics into Multimodal EHR Foundation Models
-
cs.AI, q-bio.NC updates on arXiv.org
-
Closing Gaps: An Imputation Analysis of ICU Vital Signs
arXiv:2510.24217v1 Announce Type: cross Abstract: As more Intensive Care Unit (ICU) data becomes available, the interest in developing clinical prediction models to improve healthcare protocols increases. However, the lack of data quality still hinders clinical prediction using Machine Learning (ML). Many vital sign measurements, such as heart rate, contain sizeable missing segments, leaving gaps in the data that could negatively impact prediction performance. Previous works have introduced num
Closing Gaps: An Imputation Analysis of ICU Vital Signs
-
Omics in Gastric
-
The Role of Omentin in Gastrointestinal Cancer: Diagnostic, Prognostic, and Therapeutic Perspectives
Metabolites. 2025 Sep 30;15(10):649. doi: 10.3390/metabo15100649.ABSTRACTBackground/Objectives: Omentin, also known as intelectin-1, is a secreted adipokine with anti-inflammatory, insulin-sensitizing, and immune-modulatory functions, primarily expressed in visceral adipose tissue. While omentin has been associated with favorable metabolic outcomes, its role in cancer pathogenesis appears context-dependent and remains poorly understood. This review investigates the biological functions, expressi
The Role of Omentin in Gastrointestinal Cancer: Diagnostic, Prognostic, and Therapeutic Perspectives
Metabolites. 2025 Sep 30;15(10):649. doi: 10.3390/metabo15100649.
ABSTRACT
Background/Objectives: Omentin, also known as intelectin-1, is a secreted adipokine with anti-inflammatory, insulin-sensitizing, and immune-modulatory functions, primarily expressed in visceral adipose tissue. While omentin has been associated with favorable metabolic outcomes, its role in cancer pathogenesis appears context-dependent and remains poorly understood. This review investigates the biological functions, expression patterns, and clinical relevance of omentin across gastrointestinal malignancies. Methods: A comprehensive review of the literature was conducted using PubMed, Scopus, and Web of Science up to August 2025 to evaluate the role of omentin in gastrointestinal cancers. Both preclinical and clinical studies evaluating omentin, its analogues and omentin-enhancing agents in gastric, colorectal, hepatic, pancreatic, and esophageal cancers were included. Results: Omentin exhibits anti-proliferative, anti-inflammatory, and anti-angiogenic effects within the tumor microenvironment in several GI malignancies. However, evidence also indicates a dual role. High intratumoral omentin expression correlates with improved prognosis in colorectal, gastric, and hepatic cancers; in contrast, elevated circulating levels-particularly in colorectal and pancreatic cancers-have been paradoxically associated with increased cancer risk and poor outcomes. Mechanistically, omentin modulates PI3K/Akt, NF-κB, AMPK, and oxidative stress pathways, and interacts with TMEM207. However, most available studies are small-scale and heterogeneous, with methodological inconsistencies and limited multi-omics integration, leaving major knowledge gaps. Conclusions: This review highlights omentin's distinct systemic and local roles across GI cancers, underscoring its translational implications. Omentin emerges as a promising but context-dependent biomarker and therapeutic target, with future research needed to address heterogeneity, standardize assays, and validate its clinical utility in large-scale prospective studies.
PMID:41149627 | PMC:PMC12566161 | DOI:10.3390/metabo15100649
-
(Multiomics OR Omics) AND (Pancreatic)
-
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.ABSTRACTRecent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pan
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.
ABSTRACT
Recent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pancreatic, and glioblastoma. Despite these advances, challenges remain, such as the integration of disparate data types and the interpretation of complex biological interactions. However, developments in proteogenomics and mass spectrometry have enhanced the correlation between molecular profiles and clinical features, refining the prediction of therapeutic responses. Future research in cancer drug discovery is poised to benefit from multi-omics approaches, improving the precision and efficacy of personalized therapies. By developing integrative network-based models, researchers aim to address challenges related to heterogeneity, reproducibility, and data interpretation. A standardized framework for multi-omics data integration could revolutionize cancer research, optimizing the identification of novel drug targets and enhancing our understanding of cancer biology. This complete approach holds the promise of advancing personalized therapies by fully characterizing the molecular landscape of cancer, ultimately improving patient outcomes through more effective and targeted treatment strategies. This narrative review underscores the potential of multi-omics approaches to transform cancer research and improve patient outcomes through more precise and effective treatments.
PMID:41147019 | PMC:PMC12553891 | DOI:10.1177/11795549251384582
-
cs.AI, q-bio.NC updates on arXiv.org
-
Understanding AI Trustworthiness: A Scoping Review of AIES & FAccT Articles
arXiv:2510.21293v2 Announce Type: replace Abstract: Background: Trustworthy AI serves as a foundational pillar for two major AI ethics conferences: AIES and FAccT. However, current research often adopts techno-centric approaches, focusing primarily on technical attributes such as reliability, robustness, and fairness, while overlooking the sociotechnical dimensions critical to understanding AI trustworthiness in real-world contexts. Objectives: This scoping review aims to examine how the AIES
Understanding AI Trustworthiness: A Scoping Review of AIES & FAccT Articles
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.ABSTRACTRecent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pan
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.
ABSTRACT
Recent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pancreatic, and glioblastoma. Despite these advances, challenges remain, such as the integration of disparate data types and the interpretation of complex biological interactions. However, developments in proteogenomics and mass spectrometry have enhanced the correlation between molecular profiles and clinical features, refining the prediction of therapeutic responses. Future research in cancer drug discovery is poised to benefit from multi-omics approaches, improving the precision and efficacy of personalized therapies. By developing integrative network-based models, researchers aim to address challenges related to heterogeneity, reproducibility, and data interpretation. A standardized framework for multi-omics data integration could revolutionize cancer research, optimizing the identification of novel drug targets and enhancing our understanding of cancer biology. This complete approach holds the promise of advancing personalized therapies by fully characterizing the molecular landscape of cancer, ultimately improving patient outcomes through more effective and targeted treatment strategies. This narrative review underscores the potential of multi-omics approaches to transform cancer research and improve patient outcomes through more precise and effective treatments.
PMID:41147019 | PMC:PMC12553891 | DOI:10.1177/11795549251384582
-
cs.AI, q-bio.NC updates on arXiv.org
-
Benchmarking AI Models in Software Engineering: A Review, Search Tool, and Unified Approach for Elevating Benchmark Quality
arXiv:2503.05860v2 Announce Type: replace-cross Abstract: Benchmarks are essential for unified evaluation and reproducibility. The rapid rise of Artificial Intelligence for Software Engineering (AI4SE) has produced numerous benchmarks for tasks such as code generation and bug repair. However, this proliferation has led to major challenges: (1) fragmented knowledge across tasks, (2) difficulty in selecting contextually relevant benchmarks, (3) lack of standardization in benchmark creation, and (
Benchmarking AI Models in Software Engineering: A Review, Search Tool, and Unified Approach for Elevating Benchmark Quality
-
Omics In Lung
-
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.ABSTRACTRecent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pan
Navigating Cancer Complexity: Integrative Multi-Omics Methodologies for Clinical Insights
Clin Med Insights Oncol. 2025 Oct 21;19:11795549251384582. doi: 10.1177/11795549251384582. eCollection 2025.
ABSTRACT
Recent advancements in cancer multi-omics have transformed our understanding of cancer biology by integrating genomics, transcriptomics, proteomics, and metabolomics. These integrative approaches have led to the identification of novel biomarkers and therapeutic targets, offering deeper insights into the molecular intricacies of various cancers, including breast, lung, gastric, pancreatic, and glioblastoma. Despite these advances, challenges remain, such as the integration of disparate data types and the interpretation of complex biological interactions. However, developments in proteogenomics and mass spectrometry have enhanced the correlation between molecular profiles and clinical features, refining the prediction of therapeutic responses. Future research in cancer drug discovery is poised to benefit from multi-omics approaches, improving the precision and efficacy of personalized therapies. By developing integrative network-based models, researchers aim to address challenges related to heterogeneity, reproducibility, and data interpretation. A standardized framework for multi-omics data integration could revolutionize cancer research, optimizing the identification of novel drug targets and enhancing our understanding of cancer biology. This complete approach holds the promise of advancing personalized therapies by fully characterizing the molecular landscape of cancer, ultimately improving patient outcomes through more effective and targeted treatment strategies. This narrative review underscores the potential of multi-omics approaches to transform cancer research and improve patient outcomes through more precise and effective treatments.
PMID:41147019 | PMC:PMC12553891 | DOI:10.1177/11795549251384582
-
cs.AI, q-bio.NC updates on arXiv.org
-
ProfileXAI: User-Adaptive Explainable AI
arXiv:2510.22998v1 Announce Type: new Abstract: ProfileXAI is a model- and domain-agnostic framework that couples post-hoc explainers (SHAP, LIME, Anchor) with retrieval - augmented LLMs to produce explanations for different types of users. The system indexes a multimodal knowledge base, selects an explainer per instance via quantitative criteria, and generates grounded narratives with chat-enabled prompting. On Heart Disease and Thyroid Cancer datasets, we evaluate fidelity, robustness, parsim
ProfileXAI: User-Adaptive Explainable AI
-
cs.AI, q-bio.NC updates on arXiv.org
-
Reduced AI Acceptance After the Generative AI Boom: Evidence From a Two-Wave Survey Study
arXiv:2510.23578v1 Announce Type: new Abstract: The rapid adoption of generative artificial intelligence (GenAI) technologies has led many organizations to integrate AI into their products and services, often without considering user preferences. Yet, public attitudes toward AI use, especially in impactful decision-making scenarios, are underexplored. Using a large-scale two-wave survey study (n_wave1=1514, n_wave2=1488) representative of the Swiss population, we examine shifts in public attitu
Reduced AI Acceptance After the Generative AI Boom: Evidence From a Two-Wave Survey Study
-
cs.AI, q-bio.NC updates on arXiv.org
-
Hybrid Deep Learning Framework for Enhanced Diabetic Retinopathy Detection: Integrating Traditional Features with AI-driven Insights
arXiv:2510.21810v1 Announce Type: cross Abstract: Diabetic Retinopathy (DR), a vision-threatening complication of Dia-betes Mellitus (DM), is a major global concern, particularly in India, which has one of the highest diabetic populations. Prolonged hyperglycemia damages reti-nal microvasculature, leading to DR symptoms like microaneurysms, hemor-rhages, and fluid leakage, which, if undetected, cause irreversible vision loss. Therefore, early screening is crucial as DR is asymptomatic in its in
Hybrid Deep Learning Framework for Enhanced Diabetic Retinopathy Detection: Integrating Traditional Features with AI-driven Insights
-
cs.AI, q-bio.NC updates on arXiv.org
-
Impact and Implications of Generative AI for Enterprise Architects in Agile Environments: A Systematic Literature Review
arXiv:2510.22003v1 Announce Type: cross Abstract: Generative AI (GenAI) is reshaping enterprise architecture work in agile software organizations, yet evidence on its effects remains scattered. We report a systematic literature review (SLR), following established SLR protocols of Kitchenham and PRISMA, of 1,697 records, yielding 33 studies across enterprise, solution, domain, business, and IT architect roles. GenAI most consistently supports (i) design ideation and trade-off exploration; (ii) r
Impact and Implications of Generative AI for Enterprise Architects in Agile Environments: A Systematic Literature Review
-
cs.AI, q-bio.NC updates on arXiv.org
-
Right Place, Right Time: Market Simulation-based RL for Execution Optimisation
arXiv:2510.22206v1 Announce Type: cross Abstract: Execution algorithms are vital to modern trading, they enable market participants to execute large orders while minimising market impact and transaction costs. As these algorithms grow more sophisticated, optimising them becomes increasingly challenging. In this work, we present a reinforcement learning (RL) framework for discovering optimal execution strategies, evaluated within a reactive agent-based market simulator. This simulator creates re
Right Place, Right Time: Market Simulation-based RL for Execution Optimisation
-
cs.AI, q-bio.NC updates on arXiv.org
-
Breaking Agent Backbones: Evaluating the Security of Backbone LLMs in AI Agents
arXiv:2510.22620v1 Announce Type: cross Abstract: AI agents powered by large language models (LLMs) are being deployed at scale, yet we lack a systematic understanding of how the choice of backbone LLM affects agent security. The non-deterministic sequential nature of AI agents complicates security modeling, while the integration of traditional software with AI components entangles novel LLM vulnerabilities with conventional security risks. Existing frameworks only partially address these chall
Breaking Agent Backbones: Evaluating the Security of Backbone LLMs in AI Agents
-
cs.AI, q-bio.NC updates on arXiv.org
-
What Is Your AI Agent Buying? Evaluation, Implications and Emerging Questions for Agentic E-Commerce
arXiv:2508.02630v2 Announce Type: replace Abstract: Online marketplaces will be transformed by autonomous AI agents acting on behalf of consumers. Rather than humans browsing and clicking, AI agents can parse webpages or interact through APIs to evaluate products, and transact. This raises a fundamental question: what do AI agents buy-and why? We develop ACES, a sandbox environment that pairs a platform-agnostic agent with a fully programmable mock marketplace to study this. We first explore ag
What Is Your AI Agent Buying? Evaluation, Implications and Emerging Questions for Agentic E-Commerce
-
cs.AI, q-bio.NC updates on arXiv.org
-
ReXGroundingCT: A 3D Chest CT Dataset for Segmentation of Findings from Free-Text Reports
arXiv:2507.22030v2 Announce Type: replace-cross Abstract: We introduce ReXGroundingCT, the first publicly available dataset linking free-text findings to pixel-level 3D segmentations in chest CT scans. The dataset includes 3,142 non-contrast chest CT scans paired with standardized radiology reports from CT-RATE. Construction followed a structured three-stage pipeline. First, GPT-4 was used to extract and standardize findings, descriptors, and metadata from reports originally written in Turkish
ReXGroundingCT: A 3D Chest CT Dataset for Segmentation of Findings from Free-Text Reports
-
InfoQ

-
Article: Building a RAG Application with Spring Boot, Spring AI, MongoDB Atlas Vector Search, and OpenAI
The RAG paradigm redefines AI: it combines generative models and business data for accurate, contextualised responses. The article shows how to integrate Spring Boot, Spring AI, MongoDB Atlas and OpenAI into a powerful and flexible pipeline capable of transforming the way businesses access and create value from data, with applications ranging from finance and healthcare to customer service. By Matteo Rossi
Article: Building a RAG Application with Spring Boot, Spring AI, MongoDB Atlas Vector Search, and OpenAI
The RAG paradigm redefines AI: it combines generative models and business data for accurate, contextualised responses. The article shows how to integrate Spring Boot, Spring AI, MongoDB Atlas and OpenAI into a powerful and flexible pipeline capable of transforming the way businesses access and create value from data, with applications ranging from finance and healthcare to customer service.
By Matteo Rossi-
npj Digital Medicine
-
Benchmarking large language models for personalized, biomarker-based health intervention recommendations
npj Digital Medicine, Published online: 27 October 2025; doi:10.1038/s41746-025-01996-2Benchmarking large language models for personalized, biomarker-based health intervention recommendations
Benchmarking large language models for personalized, biomarker-based health intervention recommendations
npj Digital Medicine, Published online: 27 October 2025; doi:10.1038/s41746-025-01996-2
Benchmarking large language models for personalized, biomarker-based health intervention recommendations-
cs.AI, q-bio.NC updates on arXiv.org
-
Customizing Open Source LLMs for Quantitative Medication Attribute Extraction across Heterogeneous EHR Systems
arXiv:2510.21027v1 Announce Type: new Abstract: Harmonizing medication data across Electronic Health Record (EHR) systems is a persistent barrier to monitoring medications for opioid use disorder (MOUD). In heterogeneous EHR systems, key prescription attributes are scattered across differently formatted fields and freetext notes. We present a practical framework that customizes open source large language models (LLMs), including Llama, Qwen, Gemma, and MedGemma, to extract a unified set of MOUD